NDAINTRAVENOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE (clindamycin phosphate) by Baxter is 12. First approved in 2017.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clindamycin phosphate in 0.9% sodium chloride is an intravenous antibiotic solution containing a water-soluble prodrug that converts to active clindamycin in the body. It is a lincosamide antibacterial agent used to treat infections caused by susceptible organisms across multiple body systems. The drug works by inhibiting bacterial protein synthesis, reaching peak serum concentrations within minutes of IV infusion.
Peak
Product is at peak market stage, suggesting stable commercial operations with established field teams and standard revenue trajectories.
Mechanism of Action
12.1 Mechanism of Action Clindamycin is an antibacterial drug [see ] . 12.3 Pharmacokinetics Clindamycin phosphate is a water-soluble ester prodrug of clindamycin. Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak…
Worked on CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.